Safety Of Dobutamine Stress Echocardiography Research Articles

Fatal pheochromocytoma crisis precipitated by dobutamine stress echocardiography

The safety of dobutamine stress echocardiography (DSE) has been demonstrated in multiple studies with a major complication rate of <1%. Specifically, ventricular tachycardia during DSE has a reported incidence of 0.3%, and has been bound to be of no prognostic significance in patients without obstructive coronary artery disease. We report a unique case of fatal pheochromocytoma crisis precipitated by DSE in a patient with heretofore unknown adrenal disease. We are once again reminded that no diagnostic modality is absolutely without risk; however, minimal they might be.

Letter by Schinkel et al Regarding Article, “Projected Valve Area at Normal Flow Rate Improves the Assessment of Stenosis Severity in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The Multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) Study”

To the Editor: In a recent study by Blais and colleagues,1 the authors reported the use of dobutamine stress echocardiography (DSE) in patients with low-output, low-gradient aortic valve stenosis. Clinical decision making regarding these patients is challenging, and the clinical advantage of DSE is in distinguishing truly and pseudosevere aortic stenosis and evaluating contractile reserve.2–4 The authors have not made specific recommendations about the safety of DSE in these patients, but they have stated that “in a significant proportion of …

Dobutamine stress echocardiography in women with systemic lupus erythematosus: increased occurrence of left ventricular outflow gradient.

Dobutamine stress echocardiography (DSE) is an accurate noninvasive test used for the diagnosis and evaluation of patients with known or suspected coronary artery disease (CAD). The aim of this study was to determine the rate of positive findings in DSE, to define the echocardiographic and clinical characteristics of women with systemic lupus erythematosus (SLE) and to evaluate the safety of DSE in SLE patients. Thirty consecutive SLE patients were enrolled in the study and underwent DSE study. The mean age of patients was 44 years (range 20-76). Mean duration of SLE was 8.1 years and mean SLEDAI was 5.5. None of the DSE tests performed were positive for myocardial ischaemia. A left ventricular outflow gradient (LVOG) was found in 15/28 (54%) patients who completed the test, a result higher than the reported 20% prevalence of this finding in the literature. There were no significant differences in baseline characteristics between patients who developed a gradient and patients in whom a gradient was not found. There were no significant adverse effects during the study. In the general population, LVOG has been reported to be associated with an increased rate of chest discomfort and with a significantly lower prevalence of CAD. Whether this is true for SLE patients requires further study.

Clinical Usefulness and Safety of Dobutamine Stress Echocardiography for the Detection of Significant Stenosis in the Infarcted Area

Clinical Usefulness and Safety of Dobutamine Stress Echocardiography for the Detection of Significant Stenosis in the Infarcted Area

844 Safety of dobutamine stress echocardiography in patients with aortic stenosis

844 Safety of dobutamine stress echocardiography in patients with aortic stenosis

Safety of dobutamine stress echocardiography in patients with unruptured intracranial aneurysms

Dobutamine stress echocardiography has been increasingly used for the preoperative assessment of patients who undergo major vascular surgery. The safety of this modality has been well documented in various patient subgroups, including patients with aneurysms of the aorta. No previous reports, however, have addressed the safety of this form of stress testing in patients with unruptured intracranial aneurysms. After reviewing the experience of 2 institutions, we identified 40 patients who underwent dobutamine stress echocardiography while harboring at least 1 unruptured intracranial aneurysm, and found no evidence of aneurysm instability in relation to the dobutamine infusion. Although vasodilator stress modalities should intuitively be the non-exercise stress technique of choice in these patients, stress echocardiography with the use of dobutamine appears to be safe and represents an acceptable option when used for diagnostic purposes or preoperative risk stratification in this patient population. (J Am Soc Echocardiogr 2002;15:1401-4.)

A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain

Study Objective: Chest pain in the setting of cocaine use poses a diagnostic dilemma. Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. Methods: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital. Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level. Patients exhibiting signs of continuing cocaine toxicity were excluded from the study. All patients were admitted to the hospital for serial testing after the DSE testing in the intensive diagnostic and treatment unit. Results: Twenty-four patients were enrolled. Two patients had inadequate resting images, one DSE was terminated because of inferior hypokinesis, another DSE was terminated because of a rate-related atrial conduction deficit, and 1 patient did not reach the target heart rate. Thus, 19 patients completed a DSE and reached their target heart rates. None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding sinus tachycardia). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental atropine to reach their target heart rates. Conclusion: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related chest pain. [Dribben WH, Kirk MA, Trippi JA, Cordell WH. A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain. Ann Emerg Med. July 2001;38:42-48.]

Safety of Dobutamine Stress Echocardiography Supervised by Registered Nurse Sonographers

Dobutamine stress echocardiography (DSE) is widely used for the diagnosis and evaluation of coronary artery disease. Studies examining the safety of this technique typically have involved DSE supervised by physicians. At the Mayo Clinic, experienced registered nurse (RN) sonographers were trained to perform DSE under the direct supervision of a physician. To prove that the safety of DSE was not compromised with the change in supervision, we examined data from 1035 consecutive outpatient studies: 516 patients were monitored by cardiologists or cardiology fellows (group 1) and 519 were monitored by trained RN sonographers (group 2). Risk factors, history of coronary artery disease, stress parameters, and complication rates were similar in both groups. In group 1, one patient experienced sustained ventricular tachycardia requiring treatment. In group 2, one patient experienced ventricular fibrillation during recovery and was successfully resuscitated. Outpatient DSE is safe when supervised by RN sonographers. (J Am Soc Echocardiogr 1998;11:601-5.)

Safety of Dobutamine Stress Echocardiography in Patients With Left Ventricular Apical Thrombus

We demonstrate that patients with left ventricular mural apical thrombi can safely undergo dobutamine stress echocardiography. These patients also have more severe wall motion abnormalities at rest compared with a group of patients with left ventricular dysfunction without evidence of apical thrombus.

Evolution of Dobutamine Echocardiography Protocols and Indications: Safety and Side Effects in 3,011 Studies Over 5 Years

Objectives. This study sought to document the safety of dobutamine stress echocardiography as it has evolved at a single center and to define predictors of adverse events.Background. The indications and protocol for dobutamine stress testing have evolved over 5 years of clinical use, but the influence of these changes on the safety and side effects of the test is undefined.Methods. Over 5 years, 3,011 consecutive dobutamine stress studies were performed in 2,871 patients, using an incremental protocol from 5 to 40 μg/kg body weight per min in 3-min stages, followed by atropine or an additional stage with 50 μg/kg per min, if required. Clinical data were gathered prospectively, and hemodynamic and echocardiographic findings were recorded at each stage, including recovery. Dobutamine echocardiography was defined as positive for ischemia in the presence of new or worsening wall motion abnormalities; in the absence of ischemia, failure to attain 85% of age-predicted maximal heart rate was identified as a nondiagnostic result.Results. Studies were performed for risk assessment (70%) and symptom evaluation (30%); over the study period, there was an increment in the use of dobutamine echocardiography for preoperative evaluation. Most tests (n = 2,194 [73%]) were terminated due to attainment of peak dose with achievement of target heart rate (>85% maximal age-predicted heart rate); 455 patients (15%) failed to achieve >85% maximal predicted heart rate despite maximal doses of dobutamine and atropine. The protocol was stopped prematurely in 230 patients (7.6%) because of side effects, including ventricular (n = 27 [0.9%]) and supraventricular rhythm disorders (n = 22 [0.7%]), severe hypertension (n = 24 [0.8%]) and hypotension or left ventricular outflow tract obstruction (n = 112 [3.8%]). Noncardiac symptoms, such as headache, nausea or anxiety, caused early test termination in 45 patients (1.6%). The remaining tests were stopped because of severe chest pain (n = 106 [3.5%]) or severe ischemia by echocardiography (n = 26 [0.9%]). Serious complications occurred in nine patients, including sustained ventricular tachycardia in five, myocardial infarction in one and other conditions in three requiring hospital admission (sustained supraventricular tachycardia, hypotension, suspected myocardial infarction), but neither ventricular fibrillation nor death occurred. Independent predictors of serious complications could not be defined. Over 5 years, higher dose protocols and more frequent use of atropine have raised the number of diagnostic protocols from 59% to 80%, without increasing the incidence of major side effects.Conclusions. Despite the use of more aggressive protocols and alterations of the indications for testing to include sicker patients, major side effects are a rare complication of dobutamine echocardiography.(J Am Coll Cardiol 1997;29:1234–40)

Safety of dobutamine stress echocardiography in 474 consecutive studies.

With expanding applications and increasingly aggressive stress protocols, concerns about the safety of dobutamine stress echocardiography (DSE) have arisen. The purpose of this study was to analyse prospectively the safety, adverse event profile and complication rate of DSE. Prospective data were recorded in a consecutive series of 474 patients undergoing DSE. Dobutamine was administered intravenously in graded infusion, each stage over 3 min, at 10, 20, 40 and, if required, 50 micrograms/kg/min. Atropine (1 mg) was administered thereafter if the response remained suboptimal. The mean dose of dobutamine was 42 micrograms/kg/min, with 111 patients (23%) receiving 50 micrograms/kg/min. Atropine was required for 27 patients (6%). No patient died or suffered a myocardial infarction. Sustained ventricular tachycardia occurred in one patient, angina pectoris in 127 (27%), non-sustained ventricular tachycardia in eight (2%) and supraventricular tachycardia in 19 (4%). Profound bradycardia requiring cessation of the test occurred in one patient. Pulmonary oedema developed in one patient. A hypotensive response requiring cessation of the test was seen in one patient. Test termination because the patient complained of nausea, tremor or headache was not required. DSE is safe. Side effects are rare and when they occur, are usually minor. Ischaemic pain is effectively treated by termination of the test and sublingual administration of nitrates.

Safety of dobutamine stress echocardiography. A 24 h Holter monitoring study.

Dobutamine-atropine stress echocardiography is an efficient method in the evaluation of patients with coronary artery disease. However, because high-dose dobutamine is potentially arrhythmogenic, the safety of this stress modality has been questioned. We performed a 24 h Holter monitoring, before and immediately after this test, in 73 consecutive patients (60 men and 13 women), mean age 60 +/- 12 years. Twenty-eight patients had had a recent myocardial infarction, 25 had stable chronic angina, 10 chronic ischaemic cardiomyopathy and 10 idiopathic dilated cardiomyopathy. Dobutamine was progressively increased (5-40 micrograms.kg-1.min-1) and atropine was injected in 30 patients. Arrhythmias and ST-segment deviation before and after the stress test were evaluated. The mean peak dobutamine dose was 32 +/- 11 micrograms.kg-1.min-1. The heart rate at rest and at peak dose was, respectively, 69 +/- 16 and 110 +/- 28 beats.min-1. Side effects during the injection of dobutamine were mainly ventricular (n = 14) or atrial (n = 4) premature contractions. Three patients had non-sustained ventricular tachycardia and five had hypotension during the test. No sustained episode of supraventricular or ventricular tachycardia was observed during the study. Non-sustained supraventricular and ventricular tachycardias were detected in 8 and 21 patients before and in 11 and 16 patients after dobutamine stress echocardiography (P = ns). Asymptomatic ST-segment deviation was observed in two patients before and four after dobutamine stress echocardiography. An increase in total ischaemic time (20 vs 102 mn) was observed after the test, but only five patients had ST modifications. A separate analysis of patients with and without beta-blocker did not alter these results. In addition, when the occurrence of significant arrhythmias was stratified according to a left ventricular ejection fraction threshold of 45%, we observed no difference in frequency and severity of cardiac arrhythmias. This study demonstrates that dobutamine stress echocardiography does not significantly increase arrhythmia during the following 24 h. Further studies are required to evaluate the influence of the test on ST-segment modification during the same period.

Incidence and correlates of complex ventricular arrhythmias during dobutamine stress echocardiography after acute myocardial infarction

Although previous studies have confirmed the safety of dobutamine stress echocardiography, complex ventricular arrhythmias have been reported. Our aim was (1) to identify the markers of increased arrhythmic risk during dobutamine stress echocardiography and (2) to assess whether the occurrence of major ventricular arrhythmias during the test may represent a clinically useful marker of electrical instability. Three hundred and seventy-seven consecutive survivors from acute myocardial infarction, off cardioactive therapy, underwent dobutamine stress echocardiography 11.4 days after the acute event. Holter monitoring with assessment of heart rate variability and echocardiographic determination of left ventricular ejection fraction. In addition, exercise stress testing, signal averaged ECG and coronary angiography were carried out, respectively, in 357, 150 and 273 patients. Ten subjects showed complex ventricular arrhythmias (eight non-sustained and one sustained ventricular tachycardia and one ventricular fibrillation) during dobutamine stress echocardiography (group A), whilst 366 did not (group B). Complex ventricular arrhythmias were detected by Holter monitoring in 8/10 patients in group A and 45/367 patients in group B (odds ratio 28.6, 95% CI 5.4-92.2) and by exercise testing in 4/10 patients in group A and 33/347 patients in group B (odds ratio 6.3, 95% CI 1.4-27.2). Ejection fraction < 40% was present in 3/10 patients in group A and 50/367 in group B (odds ratio 2.7, 95% CI 0.3-12.2), whilst multivessel disease was present, respectively, in 8/10 and 176/263 patients (odds ratio 1.9, 95% CI 0.3-25.5). Reduced heart rate variability and the presence of late potentials on signal averaged ECG were found in, respectively, 40/367 and 13/140 patients in group B, but none were found in group A. A total of 61 events (35 CABG, 15 PTCA, four cardiac deaths and seven non-fatal reinfarctions) occurred during the follow-up (11.4 months, range 6 to 20): four in group A and 57 in group B. No documented major arrhythmic event was reported. We conclude that (1) complex arrhythmias during dobutamine stress may occur in patients early after acute myocardial infarction; (2) the preexisting evidence of frequent, as well as repetitive, arrhythmias represents a potential marker of increased risk in this connection and, finally, (3) dobutamine-induced arrhythmias seem to represent an uncommon, even though potentially dangerous, event but not a useful new "window' on electrical instability of post-MI patients.

Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients.

The use of dobutamine stress echocardiography for the evaluation of coronary artery disease is rapidly expanding. New applications of the technique are being investigated in a wide variety of patients including those with advanced coronary artery disease. Despite its widespread use, the safety of dobutamine stress echocardiography has not been sufficiently documented. A consecutive series of 1118 patients undergoing dobutamine stress echocardiography for evaluation of known or suspected coronary artery disease form the basis of this report. Dobutamine stress testing was performed for evaluation of chest pain, risk assessment before noncardiac surgery, after recent myocardial infarction, or as a part of ongoing research protocols. Over the study period, the maximal dose of dobutamine used was increased from 30 to 50 micrograms/kg per minute, and atropine was used in 420 (37%) patients. There were no occurrences of death, myocardial infarction, or episodes of sustained ventricular tachycardia as a result of dobutamine stress testing. The major reasons for test termination were achievement of target heart rate in 583 patients (52.1%), maximum dose in 255 (22.8%), and angina pectoris in 142 (13%). The test was terminated in 36 (3%) patients because of noncardiac side effects including nausea, anxiety, headache, tremor, and urgency. Angina pectoris occurred in 216 (19.3%) patients. Sublingual nitroglycerin, a short-acting beta-blocker, or both types of medication were administered in 80 of these patients for relief of angina pectoris. None required intravenous nitroglycerin. A total of 736 (65%) patients had stable sinus rhythm throughout the test. The most common arrhythmias were frequent premature ventricular complexes (six or more per minute) in 172 patients (15%), and frequent premature atrial complexes in 86 (8%). There were 40 patients with nonsustained ventricular tachycardia. None had symptoms associated with the tachycardia, and only one received specific pharmacological treatment to prevent recurrence of the arrhythmia after the test was terminated. The patients who were evaluated after recent myocardial infarction and those who received atropine did not have a higher frequency of ventricular tachycardia compared with those without recent infarction and those not receiving atropine. Dobutamine stress echocardiography was safely performed using supplemental atropine and an aggressive dosing protocol. Noncardiac side effects were usually minor. Arrhythmias were well tolerated and rarely required treatment. In this study, serious complications from myocardial ischemia did not occur. Symptomatic ischemia was effectively treated with test termination, sublingual nitroglycerin, or short-acting beta-blockers.